AUTHORS
Deyan Yosifov, PhD, Eugen Tausch, MD, PhD2, Christof Schneider, MD3, Sandra Robrecht, MD, PhD4, Adam Giza5, Othman Al-Sawaf, MD, PhD6, Moritz Fürstenau, MD7, Carsten Utoft Niemann, MD, PhD8, Arnon Philip Kater, MD, PhD9, Kirsten Fischer, MD10, Michael Hallek Jr, MD11, Barbara Eichhorst, MD12, Stephan Stilgenbauer, MD13
AFFILIATIONS
1 Division of CLL, Department III of Internal Medicine, Ulm University Hospital, Ulm, Germany
2 Comprehensive Cancer Center Ulm (CCCU), Department III of Internal Medicine, Ulm University Hospital, Ulm, Germany, Division of CLL, Department III of Internal Medicine, Ulm University Hospital, Ulm, Germany
3 Comprehensive Cancer Center Ulm (CCCU), Department III of Internal Medicine, Ulm University Hospital, Ulm, Germany, Division of CLL, Department III of Internal Medicine, Ulm University Hospital, Ulm, Germany
4 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
5 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
6 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
7 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
8 Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
9 Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands
10 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
11 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
12 Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
13 Comprehensive Cancer Center Ulm (CCCU), Department III of Internal Medicine, Ulm University Hospital, Ulm, Germany, Division of CLL, Department III of Internal Medicine, Ulm University Hospital, Ulm, Germany
ABSTRACT
INTRODUCTION: IGLV3-21R110 (R110) is a point mutation that can enable autonomous signaling of B cell receptors using light chains encoded by allele ∗01 or ∗04 of IGLV3-21. Chronic lymphocytic leukemia (CLL) patients (pts) with R110 were reported to have shorter time to first treatment (TTFT) and overall survival (OS) under chemoimmunotherapy (CIT), independent of their IGHV mutational status. We previously reported shorter TTFT and event-free survival of R110+ early-stage CLL pts under watch & wait, placebo or ibrutinib treatment in the CLL12 trial. In contrast, analyses of venetoclax-based regimens (VBR) in the HOVON-139 and HOVON-141/VISION trials did not demonstrate an association of R110 with response rate, minimal residual disease or progression-free survival (PFS). However, the current evidence remains limited by the small sample size and/or retrospective design of most of the previous studies.
METHODS: We analyzed samples from 2227 of 2327 previously untreated pts enrolled in 4 randomized phase 3 trials of the German CLL Study Group: CLL8 (CIT arm only), CLL10, GAIA-CLL13 and CLL14 (in total 1318 pts treated with CIT and 909 with VBR). The IGLV3-21 locus was sequenced via targeted next generation sequencing; 77 samples with ambiguous results were additionally analyzed by Sanger sequencing and/or PCR. Survival analyses were performed to assess the association of R110 with PFS, the primary endpoint of all 4 trials, and OS.
RESULTS: R110 was present in 295 (13.3%) of 2220 samples with unambiguous results: 42 (13.4%) in CLL8, 74 (13.2%) in CLL10, 131 (14.2%) in GAIA-CLL13 and 48 (11.4%) in CLL14. Of 2151 pts with available IGHV mutational and R110 status, 60% had unmutated IGHV (U-CLL) and 40% had mutated IGHV (M-CLL). In R110+ pts, the median IGHV germline identity was 97.92% (range 87.22-99.66%). None of the R110+ pts had del(17p), whereas this aberration was present in 2.8% of R110- pts (p<0.001). Mutated TP53 was present in 2% of R110+ and 5.3% of R110- pts (p=0.013). The low overall frequency of del(17p) and TP53 mutations reflects the exclusion of pts with these abnormalities in CLL10 and GAIA-CLL13. When comparing R110+ and R110- pts, differences were also observed regarding presence of trisomy 12 (1.4% vs 17.8%, p<0.001) and del(13q) (72.7% vs 53.5%, p<0.001), Binet stage A (14.6% vs 22.3%, p=0.002) and high or very high risk according to CLL-IPI (42.7% vs 51.2%, p=0.001). Other characteristics, incl. del(11q), age, sex, ECOG performance status, comorbidities, creat. clearance, B symptoms, serum β2-microglobulin and thymidine kinase did not differ significantly between R110+ and R110- pts (all p>0.05).
At a median follow-up of 71.6 months (interquartile range 62.1-80.5), 1179 PFS and 418 OS events had occurred. PFS did not differ between pts with and without R110 (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.82-1.15, p=0.749), with similar findings among pts treated with CIT (HR 1.01, 95%CI 0.83-1.22, p=0.951) or VBR (HR 0.84, 95%CI 0.61-1.17, p=0.307). OS was likewise not different in the overall cohort (HR 0.85, 95%CI 0.63-1.14, p=0.264), as well as among pts treated with CIT (HR 0.88, 95%CI 0.64-1.22, p=0.444) or VBR (HR 0.64, 95%CI 0.31-1.32, p=0.224). VBR retained superiority over CIT in R110+ pts regarding both PFS (HR 0.43, 95%CI 0.3-0.61, p<0.001) and OS (HR 0.33, 95%CI 0.16-0.7, p=0.004).
When analyzed according to IGHV mutational status, R110 was associated with shorter PFS (HR 1.72, 95%CI 1.34-2.21, p<0.001) and OS (HR 1.53, 95%CI 1-2.32, p=0.049) in M-CLL pts but not in U-CLL pts (PFS: HR 0.86, 95%CI 0.68-1.1, p=0.227; OS: HR 0.68, 95%CI 0.43-1.08, p=0.101). The impact of R110 on PFS and OS in M-CLL was limited to pts treated with CIT (PFS: HR 1.87, 95%CI 1.4-2.5, p<0.001; OS: HR 1.69, 95%CI 1.06-2.68, p=0.027) and was not observed with VBR (PFS: HR 1.2, 95%CI 0.71-2.01, p=0.494; OS: HR 0.84, 95%CI 0.29-2.45, p=0.749).
CONCLUSIONS: R110 was detected in 13.3% of 2220 CLL pts requiring first-line therapy – the largest cohort evaluated for clinical outcomes with R110 so far. R110 describes a population with an intermediate IGHV mutational status and an intermediate prognosis. Accordingly, it was not confirmed as a prognostic factor in the full cohort but was associated with shorter PFS and OS in M-CLL pts treated with CIT. These results are in line with previous findings with continuous ibrutinib in early-stage CLL enriched for M-CLL cases. Efficacy of VBR was unaffected by presence of R110.
DISCLOSURES
Deyan Yosifov, PhD: No relevant conflicts of interest to declare.